RTP Mobile Logo
Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of HER2-Positive Breast Cancer (Webinar Video Proceedings)
Released July 2021

Featuring perspectives from Drs Erika Hamilton, Ian Krop, and Joyce O’Shaughnessy. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Evaluate published research data in guiding the selection of therapy for patients with HER2-positive localized breast cancer.
    • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, including in patients with CNS metastases, incorporating current and recently approved anti-HER2 therapies.
    • Develop an understanding of the mechanisms of action of margetuximab, trastuzumab deruxtecan, tucatinib and neratinib and the clinical trial findings leading to the FDA approvals of these agents for previously treated, advanced HER2-positive breast cancer.
    • Recognize common and rare side effects associated with novel anti-HER2 agents, and develop supportive management strategies to prevent and ameliorate these toxicities for patients with HER2-positive breast cancer.
    • Appraise recent FDA approvals of and ongoing clinical research evaluating novel agents and treatment strategies for HER2-positive breast cancer, and counsel patients regarding protocol and nonresearch treatment recommendations.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOHER2BC21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCOHER2BC21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOHER2BC21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCOHER2BC21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Erika Hamilton, MD
    Director, Breast and Gynecologic Research Program
    Sarah Cannon Research Institute/Tennessee Oncology
    Nashville, Tennessee

    Advisory Committee and Consulting Agreements (No Personal Fees): Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Lilly, Merck, Mersana Therapeutics, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Silverback Therapeutics; Contracted Research (to Institution Only): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana Farber Cancer Hospital, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, InventisBio, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics, Merus BV, Molecular Templates, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Orinove Inc, Pfizer Inc, PharmaMar, Plexxikon Inc, Polyphor, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Torque Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks.

    Ian E Krop, MD, PhD
    Associate Chief, Division of Breast Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc; Contracted Research: Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Merck, Novartis.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Oncology; Speakers Bureau: Lilly, Pfizer Inc, Seagen Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Inc, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seagen Inc.

    Release date: July 2021
    Expiration date: July 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):